New Covid-19 vaccine said to be ‘90% effective’ in continuing trials

by Gazette Reporter
0 comment

A vaccine developed by Pfizer and German partner BioNTech was 90% effective in preventing Covid-19 infections in trials, it has been announced.

The companies revealed the news in a statement today, saying the vaccine was effective in preventing Covid-19 infections in ongoing Phase 3 trials.

According to initial findings, protection in patients was achieved seven days after the second of two doses, and 28 days after the first.

In a statement, Pfizer chairman and CEO, Albert Bourla, said: “We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.

“We are reaching this critical milestone in our vaccine development programme at a time when the world needs it most.”

The companies said they expect to supply up to 50 million vaccine doses globally in 2020, and up to 1.3 billion doses in 2021, according to supply projections.

Phase 3 of vaccine trials is when the drug is given to thousands of people and tested for efficacy and safety. When approved and licenced, the vaccine will then enter into Phase 4.

News of the vaccine comes after Pfizer announced just last week that they would be creating jobs at their manufacturing sites at Grange Castle, Newbridge, and Cork. Approximately €300m will be invested into the three sites to support their development.

Related Articles